Regulation FD Disclosure. On October 6, 2026, the Company issued a press release announcing the Private Placement. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the…

Unregistered Sales of Equity Securities. The information set forth in

Entry into a Material Definitive Agreement. PIPE Financing On October 5, 2026, Telomir Pharmaceuticals, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Purchase Agreement ”) with various investors (the “ Investors ”), pursuant to which the Company agreed to issue and sell to the Investors in a private placement (the “ Private Placement ”) 4,843,300 shares (the “ Shares ”) of the Company’s common stock, no par value (the “ Common Stock ”). The securities sold to the…

Regulation FD Disclosure. On September 17, 2026, Telomir Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the publication of a peer-reviewed preclinical study titled “Targeted Intracellular Metal Modulation Attenuates Oxidative Stress and Preserves Retinal Integrity and Function in a Zebrafish Model of Mitochondrial Dysfunction and Age-Related Retinal Degeneration” in International Journal of Molecular Sciences . 2026; 27(18), 8265. The publication demonstrated that Tel…

Regulation FD Disclosure. On September 14, 2026, Telomir Pharmaceuticals, Inc. (the “Company”) issued a press release announcing new research findings from The Ohio State University College of Veterinary Medicine demonstrating that Telomir-Zn produces inhibition of cell growth across human and canine osteosarcoma models. The study examined Telomir-Zn across three osteosarcoma cell line models: HOS (human), D17 (canine), and Abrams (canine). Researchers evaluated the dose-dependent anti-tumor…

Regulation FD Disclosure. On August 10, 2026, Telomir Pharmaceuticals, Inc. (the “Company”) issued a press release announcing publication of a peer-reviewed preclinical study titled “Telomir-Zn Modulates Intracellular Iron and Copper to Inhibit JmjC Histone Demethylases and Suppress Tumor Growth in Prostate and Triple-Negative Breast Cancer” in the Journal of Oncology Research and Therapy, Volume 11, Issue 3. The publication demonstrated that Telomir-Zn inhibits histone demethylases (KDMs), w…

Chief Financial Officer — Alan Weichselbaum: The departure of the CFO without any stated disagreement and subsequent appointment of a fractional CFO.

Completion of Acquisition or Disposition of Assets The information contained in

Unregistered Sales of Equity Securities. The information contained in

Entry into a Material Definitive Agreement On April 22, 2026, Telomir Pharmaceuticals, Inc. (the “Company”) completed its acquisition of TELI Pharmaceuticals, Inc. (“TELI”) pursuant to the previously announced merger agreement (the “Transaction”). The Transaction was previously approved by the Company’s shareholders during the Company’s annual shareholders meeting on March 23, 2026. At closing, the Company acquired 100% of TELI in exchange for a total of 34,389,710 restricted shares of the Co…

The filing pertains to an amendment of the company's incentive plan and is not related to any management change.

Other Events Telomir Pharmaceuticals Reports New Cellular Data Supporting an Epigenetic Modulation Mechanism Implicated in Cancer and Aging Cellular findings show Telomir-Zn modulates intracellular metal balance linked to oxidative stress, mitochondrial dysfunction, DNA methylation instability, and genomic integrity—without relying on cytotoxic mechanisms. On February 5, 2026, Telomir Pharmaceuticals, Inc. (the “Company”) reported new findings from preclinical cellular studies evaluating its…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On November 20, 2025, Telomir Pharmaceuticals, Inc. (the “Company”) submitted its preliminary proxy statement on Schedule 14A to the Securities and Exchange Commission (the “SEC”) in connection with its annual meeting of shareholders. At that time, the Company had planned to hold its annual meeting of shareholders on December 30, 2025, subject to completion of the SEC review process. The preli…

Other Events Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) (the “Company”) is reporting results from a completed preclinical efficacy study evaluating Telomir-1 (Zn-Telomir) in zebrafish tumor xenograft animal models of triple-negative breast cancer (“TNBC”). The study was conducted in collaboration with BioReperia using its ZTX® ONCOLEADS plat…

The filing details compensation and incentive actions for the CEO, Erez Aminov.

Director — Craig Eagle: Mr. Craig Eagle resigned from the Board of Directors.

Entry into a Material Definitive Agreement Telomir Pharmaceuticals Executes Binding LOI for Worldwide Rights to Telomir-1, Positioning the Company for Global Market Expansion and Value Growth Unifying global IP rights and enabling up to $5 million in potential shareholder contributions, the agreement strengthens Telomir’s foundation for partnerships, licensing, and long-term value creation . On October 17, 2025, Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) (“Telomir” or the “Company”) entered…

Other Events Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Inhibits Key Epigenetic Enzymes Driving Tumor Growth, Autoimmune Disease, Neurodegeneration, and Metabolic Dysfunction New data from Eurofins Discovery show that Telomir-1 blocks enzymes that drive disease by turning off critical genes—highlighting its potential to treat cancer, autoimmune conditions, neurodegeneration, and metabolic disorders through epigenetic modulation. On August 7, 2025, Telomir Pharmaceutical…

Other Events Telomir Pharmaceuticals Reports Telomir-1 Demonstrates a Rare Mitochondrial Activity Profile by Selectively Restoring Energy and Improving Oxidative Balance in Diseased Human Cell Lines Without Causing Them to Divide Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) today reported new preclinical results showing that its lead compound, Telomir-1, restored mitochondrial function without triggering oxidative stress or cell proliferation in human cells derived from a patient with Hutchin…

Entry into a Material Definitive Agreement. The information set forth in

Unregistered Sales of Equity Securities. The information set forth in

Unregistered Sales of Equity Securities. The information set forth in

Other Events Telomir Pharmaceuticals Secures $3 Million at a Premium in Straight Equity Sale Involving No Warrants to Advance Rare Disease IND Investment from largest shareholder strengthens balance sheet, signals insider conviction, and funds Telomir-1’s upcoming IND submission for a rare disease indication On May 19, 2025, Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) (the “Company”) raised $3 million in equity financing through a direct investment by The Bayshore Trust, an entity affiliated…

Chief Financial Officer, Treasurer, Secretary — Michelle Yanez: Ms. Yanez resigned from her positions as CFO, Treasurer, and Secretary.

Other Events Telomir Pharmaceuticals Demonstrates Telomir-1 Reverses Key Drivers of Cellular Decline in Human Cell Lines Supporting Therapeutic Potential in Autism and Spasmodic Dysphonia Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) (“Telomir”), a leader in age-reversal science, today announced new preclinical data showing that its lead oral drug candidate, Telomir-1, reverses multiple hallmarks of cellular decline across several human cell lines. The findings include improved mitochondrial ac…